IM Therapeutics emerges from stealth with small molecule for T1D

ImmunoMolecular Therapeutics LLC (Broomfield, Colo.) emerged from stealth mode with a small molecule candidate that aims to treat Type I diabetes by preventing the initiation of the autoimmune response against insulin-producing beta cells.

The company was founded in 2015 based on research at the University of Colorado that suggested human leukocyte antigen (HLA) molecules can "mis-present" autoantigens to immune cells, initiating an autoimmune response. The co-founders' research suggested that blocking the major histocompatibility complex class II DQ8 (HLA-DQ8) allele could prevent the presentation of autoantigens to immune cells, thereby preventing the development of Type I diabetes...